ClinicalTrials.gg
CompletedNCT06119750Updated Nov 7, 2023

4-Day Primary Irritation Patch Test of MIS Solution

An interventional study of NS Solution and Normal Saline in Healthy, Irritation/Irritant and Reactions Adverse, sponsored by Next Science TM. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Next Science TM · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry.
  • Registered 2 years 9 months after the study started (first participant enrolled Jul 2020, registered Apr 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a 7 day primary irritation patch test. This study investigates the irritation potential of Next Science MIS Wound Irrigation Solution under standardized conditions compared with an inert control (normal saline) and a known irritant, 20% sodium dodecyl sulfate (also known as sodium lauryl sulfate [SLS]) solution in deionized water [DI] water) on intact skin of healthy human subjects.

Read the detailed description

In accordance with ISO 10993-10:2010(E), study products will be delivered via dermal patch at 15 and 30 minutes (min) and up to 1-hour (h), 2-h, 3-h, 4-h and then, pending results, 24-h (evaluated up to at least 48-h) continuous exposure. Response rate will be evaluated immediately after application then 1 h, 2 h, 24 h, 48 h, and then 72 h post-exposure.

02

Conditions studied

  • Healthy
  • Irritation/Irritant
  • Reactions Adverse
03

In context

Lead sponsor

Next Science TM is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals eligible for inclusion in the study were those who:

    1. Were male or female, 18 - 75 years of age, in general good health (confirmed by medical history);
    2. If females of , were using an acceptable form of (i.e., oral contraceptive, intra-uterine device [IUD], diaphragm, condom, abstinence, bilateral tubal ligation, or are in a monogamous relationship with a partner who had a vasectomy);
    3. In the case of females of childbearing potential, had a negative urine pregnancy test (UPT) at Screening (a woman was considered to be of non-childbearing potential if she was for at least 12 months or was surgically sterile [hysterectomy, bilateral oophorectomy]);
    4. Agreed not to use systemic/topical within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;
    5. Agreed not to use systemic/topical analgesics such as aspirin (81 mg daily aspirin were allowed at the discretion of the Investigator), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen was permitted);
    6. Were free of any systemic or dermatologic disorder which, in the opinion of the investigative personnel, interfered with the study results or increased the risk of adverse events (AEs);
    7. Were of any skin type or race providing the skin pigmentation allowed for discernment of erythema;
    8. Completed a medical screening procedure; and
    9. Read, understood, and signed an agreement

Exclusion criteria

Exclusion Criteria:

  • Had any visible skin disease at the study site which, in the opinion of the investigative personnel, would have interfered with the evaluation; 2. Were receiving systematic or topical drugs or medication which, in the opinion of the investigative personnel, would have interfered with the study results; 3. Had psoriasis and/or active atopic dermatitis/eczema; and/or 4. Had a known sensitivity to cosmetics, skin care products, or topical drugs as related to the material being evaluated. 5. Had a history of allergies or sensitivity to study material being tested. 6. Were pregnant women. 7. Were women who were breast-feeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    MIS Solution

    device under investigation

    Device: NS Solution

  • Placebo comparator
    Saline

    0.9%

    Other: Normal Saline

  • Active comparator
    Sodium Lauryl Sulfate

    20%

    Other: SLS

Interventions

  • DeviceNS Solution

    This will be administered via skin patch.

    Also known as: Antimicrobial Solution

  • OtherNormal Saline

    This will be administered via skin patch.

    Also known as: Negative Control

  • OtherSLS

    This will be administered via skin patch.

    Also known as: Positive Control

06

What researchers measure

Primary outcomes

  1. To evaluate the effects of wound solution on healthy volunteers when applied to the skin.

    Response Grade of Irritation

    Time frame: 7 days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06119750
Lead sponsor
Next Science TM
Collaborators
TKL Research, Inc.
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Jul 6, 2020
Primary completion
Jul 16, 2020
Completion
Aug 4, 2020
Last update
Nov 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion